Drug Trial Radar · NCT03876717
Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea
Last checked: Nov 19, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
255
Actual
Start
Oct 25, 2018
Primary completion
Jul 1, 2021
Study completion Feb 13, 2022
Sponsor
- Lead sponsor
- Lars Kristian MunckAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pierre and Marie Curie University
- First posted
- Mar 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bile acid diarrhoea is a chronic disease that impairs quality of life. One in 100 has the condition and many suffer from the disease without knowing. The current test is called SeHCAT and is expensive and time-consuming and is unavailable in many places, including the US. The disease is often misdiagnosed as irritable bowel syndrome and estimated one third of patients with irritable bowel syndrome of the mixed type and the diarrhoea predominant type suffer from bile acid diarrhoea without knowing. A blood test called 7α-hydroxy-4-cholestene-3-one (C4) could make it much easier to diagnose bile acid diarrhoea. To establish the new test, the results of both C4 and SeHCAT are compared with the treatment effect of the drug called colesevelam. We invite patients who are referred for the SeHCAT test to participate in the trial. The SeHCAT test takes two days that are one week apart. The study patients register stool habits with a diary in the week between the SeHCAT visits. Based on the diary results, we screen for eligibility; e.g. a certain degree/severity of diarrhoea is required for participation. We treat eligible study patients (i.e those with diarrhoea) with either colesevelam or placebo (medicine without effect) that is randomly assigned. 170 study patients need to complete the treatment. We aim to validate (ie. compare) both the C4-test and the SeHCAT test with the colesevelam treatment response as the reference.
Conditions
- Bile Acid Malabsorption
- Chronic Diarrhea
Interventions
Colesevelam HydrochlorideDrug
Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
Placebo oral capsuleDrug
Inactive placebo tablets over-encapsulated with DB caps AAA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intention-to-treat diarrhoea remission rate defined by the Hjortswang criteria for colesevelam in patients with BAD defined by C4 > 46 ng/mLTime frame: Intervention days 6 through 12 (last seven intervention days)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Hvidovre University Hospital
Hvidovre, Denmark
Zealand University Hospital
Køge, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.